Pathologically proven unresectable adenocarcinoma of stomach 
With uni-dimensionally measurable disease (at least longest diameter 2 cm on conventional CT scan, x-ray or physical examination, or 1cm on spiral CT scan) 
Age 18 to 70 years old 
Estimated life expectancy of more than 3 months 
ECOG performance status of 2 or lower 
Adequate bone marrow function(absolute neutrophil count [ANC] ≥1,500/µL, hemoglobin ≥9.0 g/dL,and platelets ≥100,000/µL) 
Adequate kidney function (serum creatinine < 1.5 mg/dL) 
Adequate liver function (serum total bilirubin < 2 times the upper normal limit (UNL); serum transaminases levels <3 times [<5 times for patients with liver metastasis] UNL) 
No prior chemotherapy but prior adjuvant chemotherapy finished at least 6 months before enrollment was allowed. (but, prior adjuvant chemotherapy with capecitabine or S-1 or camptothecin analogues was excluded) 
No prior radiation therapy for at least 4 weeks before enrollment in the study 

NCT00343668_inc_T1
Condition
adenocarcinoma of stomach
NCT00343668_inc_T2
Qualifier
unresectable
NCT00343668_inc_T3
Measurement
Pathologically
NCT00343668_inc_T4
Value
proven
NCT00343668_inc_T5
Condition
disease
NCT00343668_inc_T6
Qualifier
uni-dimensionally measurable
NCT00343668_inc_T7
Measurement
longest diameter
NCT00343668_inc_T8
Procedure
conventional CT scan
NCT00343668_inc_T9
Value
at least 2 cm
NCT00343668_inc_T10
Procedure
x-ray
NCT00343668_inc_T11
Procedure
physical examination
NCT00343668_inc_T13
Procedure
spiral CT scan
NCT00343668_inc_T14
Measurement
longest diameter
NCT00343668_inc_T15
Value
at least 1cm
NCT00343668_inc_T12
Scope
at least longest diameter 2 cm on conventional CT scan, x-ray or physical examination, or 1cm on spiral CT scan
NCT00343668_inc_T16
Person
Age
NCT00343668_inc_T17
Value
18 to 70 years old
NCT00343668_inc_T18
Measurement
Estimated life expectancy
NCT00343668_inc_T19
Value
more than 3 months
NCT00343668_inc_T20
Measurement
ECOG performance status
NCT00343668_inc_T21
Value
2 or lower
NCT00343668_inc_T22
Measurement
bone marrow function
NCT00343668_inc_T23
Value
Adequate
NCT00343668_inc_T24
Measurement
absolute neutrophil count [ANC]
NCT00343668_inc_T25
Value
≥1,500/µL
NCT00343668_inc_T26
Measurement
hemoglobin
NCT00343668_inc_T27
Value
≥9.0 g/dL
NCT00343668_inc_T28
Measurement
platelets
NCT00343668_inc_T29
Value
≥100,000/µL
NCT00343668_inc_T30
Scope
absolute neutrophil count [ANC] ≥1,500/µL, hemoglobin ≥9.0 g/dL,and platelets ≥100,000/µL
NCT00343668_inc_T31
Measurement
kidney function
NCT00343668_inc_T32
Value
Adequate
NCT00343668_inc_T33
Measurement
serum creatinine
NCT00343668_inc_T34
Value
< 1.5 mg/dL
NCT00343668_inc_T35
Measurement
liver function
NCT00343668_inc_T36
Value
Adequate
NCT00343668_inc_T37
Measurement
serum total bilirubin
NCT00343668_inc_T38
Value
< 2 times the upper normal limit (UNL)
NCT00343668_inc_T39
Measurement
serum transaminases levels
NCT00343668_inc_T40
Value
<3 times UNL
NCT00343668_inc_T41
Condition
liver metastasis
NCT00343668_inc_T42
Value
<5 times UNL
NCT00343668_inc_T43
Scope
<3 times [<5 times for patients with liver metastasis] UNL
NCT00343668_inc_T44
Scope
serum total bilirubin < 2 times the upper normal limit (UNL); serum transaminases levels <3 times [<5 times for patients with liver metastasis] UNL
NCT00343668_inc_T45
Procedure
chemotherapy
NCT00343668_inc_T46
Temporal
prior
NCT00343668_inc_T47
Negation
No
NCT00343668_inc_T48
Procedure
adjuvant chemotherapy
NCT00343668_inc_T49
Temporal
prior
NCT00343668_inc_T50
Temporal
at least 6 months before enrollment
NCT00343668_inc_T51
Procedure
adjuvant chemotherapy
NCT00343668_inc_T52
Temporal
prior
NCT00343668_inc_T53
Drug
capecitabine
NCT00343668_inc_T54
Drug
S-1
NCT00343668_inc_T55
Drug
camptothecin analogues
NCT00343668_inc_T56
Negation
excluded
NCT00343668_inc_T57
Procedure
radiation therapy
NCT00343668_inc_T58
Temporal
at least 4 weeks before enrollment
NCT00343668_inc_T59
Negation
No
NCT00343668_inc_T60
Temporal
prior
NCT00343668_inc_T61
Reference_point
enrollment
NCT00343668_inc_T62
Negation
was allowed
NCT00343668_inc_T63
Scope
prior adjuvant chemotherapy finished at least 6 months before enrollment was allowed
NCT00343668_inc_T64
Reference_point
enrollment